News Focus
News Focus
icon url

zen222

02/14/19 12:33 AM

#1196 RE: joe117 #1195

That is correct, and it should also be noted that everyone InventaBioTech owes money to is "friendly" to the company (board members, early investors, and other insiders) so the odds of them diluting the stock in any serious way are less than zero.
icon url

chemist72

02/15/19 11:24 AM

#1197 RE: joe117 #1195

Don't be fooled. These convertible promissory notes have already been signed (on Jan. 31, 2019) and monies have been given/loaned to INVB. These notes are not "sold", but are held by the lenders, Sue Lynn Hui and Shing Leong Hui. The good news is that both of these persons are INVB board members. They will have a strong incentive to get their money back (The maturity date of the Notes is January 31, 2020).

Presumably they will do their best to see that INVB becomes profitable so that their "loan (including interest)" may be paid back in cash. If not, they will receive shares of INVB that will be valued at $.20 per share (this is called the Conversion Price in a Promissory Note).

The note holders are entitled to, at their option, convert all or any amount of the principal face amount and any accrued but unpaid interest of the Notes into Common Stock, at any time, at a conversion price for each share of Common Stock equal to $0.20.

The sections above in italics are copied and pasted directly from the 8-K referenced in my original post.

So there it is in a nutshell. Two Promissory notes have been agreed to and monies have been loaned to INVB that must be paid back on or before 1/31/2020 either in cash or in INVB shares. This has nothing to do with notes being sold. They have already been signed and agreed to.